Bayer: Future of HCC Care Management: Evaluation and Application of the Sorafenib to Regorafenib Sequence

 Industry Symposium

Plenary
English
Industry symposium
02 March 2018 19:30 - 20:30

Bayer

G.COM.SM.ON.02.2018.2376 
L.CH.MKT.ONC.02.2018.0568-EN

Presentations

Opening remarks by the Chair
Jordi Bruix - Spain
02 March 2018 19:30 - 19:35

Sequential therapy in HCC: Patient considerations and other decision factors
Amit Singal - United States
02 March 2018 19:35 - 19:50

Q&A
Amit Singal - United States
02 March 2018 19:50 - 19:55

Treatment of HCC: Optimizing window of opportunity to prolong OS
Arndt Vogel - Germany
02 March 2018 19:55 - 20:05

Q&A
Arndt Vogel - Germany
02 March 2018 20:05 - 20:10

Critical analysis of recent clinical evidence in HCC
Pierre Gholam - United States
02 March 2018 20:10 - 20:20

Q&A
Pierre Gholam - United States
02 March 2018 20:20 - 20:25

Closing remarks by the Chair
Jordi Bruix - Spain
02 March 2018 20:25 - 20:30